Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

and cash equivalents

$  71,074,807$
5,893,970Accounts receivable, net of allowances

4,505,4115,145,494Inventories

6,874,5997,683,842Other current assets

3,423,5742,315,536Total current assets

85,878,39181,038,842Property and equipment, net

1,198,8051,220,010Intangible assets, net

7,029,1867,427,223Other assets

1,972,2842,367,979Total assets

$  96,078,666$
92,054,054LIABILITIES AND EQUITYCurrent liabilities:Current portion of long-term debt

$
-$
2,666,668Accounts payable

3,280,2892,124,654Other current liabilities

4,172,9424,436,298Total current liabilities

7,453,2319,227,620Revolving line of credit

4,575,9511,825,951Long-term debt, excluding current portion

-2,666,665Other long-term obligations, excluding current portion

592,427618,343Total liabilities

12,621,60914,338,579Commitments and contingenciesEquity:Shareholders' equity:Common stock - no par value; 100,000,000 shares authorized;20,215,910 and 20,338,461 shares issued and outstandingas of September 30, 2011 and December 31, 2010, respectively

71,802,06870,778,874Retained earnings

11,744,9976,998,806Total shareholders' equity

83,547,06577,777,680Noncontrolling interests

(90,008)(62,205)Total equity

83,457,05777,715,475Total liabilities and equity

$  96,078,666$
92,054,054CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Income(Unaudited)Three months ended September 30,Nine months ended September 30,2011201020112010Net revenues

$
3,054,278$
2,190,870$
38,110,946$
33,061,457Costs and expenses:Cost of products sold

1,341,256909,4343,411,3542,632,447Selling and marketing

5,060,5465,692,04816,253,57417,147,683Research and development

1,233,0251,138,9553,269,7462,947,623General and administrative

2,117,6841,806,9756,442,1395,471,012Amortization of
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., a ... in epilepsy and related neurological disorders, is today reporting ... lead compound INS001 in patients with drug-resistant epilepsy.  The ... Device Trials (AED) Xll meeting by Dr. ... Chairman of Insero,s Scientific Advisory Board.  In this study, ...
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Tooth decay is ... showing active signs of the disease. The World Health Organization ... nearly 100% of adults have cavities. What are the long-term ... is showing a strong connection between the oral bacterial imbalance ... this disease so rampant, yet it is also 100% preventable? ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... VAP Cholesterol test can help doctors and clinicians identify ... options for patients at risk of heart disease, ... a,new cholesterol-fighting drug combination point to the need for ... other,lipids. That,s according to Atherotech, a cardio-diagnostic company that,has ...
... ABAX ), a medical products company manufacturing point-of-care,blood ... its,financial results for the third quarter of fiscal year ... 4:15 p.m. ET, Thursday, January 31, 2008., Participants ... the,conference call, or can listen via a live Internet ...
... ARIUS, Product Candidate Trop-2 Signal ... Transduction Antibody ... a full-,service biopharmaceutical development and protein production company, today,announced that ... Research, Inc., a biotechnology company focused on discovering,and developing the ...
Cached Biology Technology:Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 3Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3
(Date:5/17/2013)... New Jersey, and City University of New York have ... that effectively clears organisms to be viewed under microscopes. ... which is one of the few high-quality clearing solutions ... Drug Enforcement Administration (DEA) due to its use as ... vital for viewing organisms under a microscope. Without them, ...
(Date:5/17/2013)... College study finds human-caused climate change may have ... contradicting a host of recent studies that predict ... , The findings, which appear in the journal ... for survival of a creature thought to be ... tropical cold-blooded animals, especially forest lizards, will be ...
(Date:5/16/2013)... MD FASEB MARC (Maximizing Access to Research ... for The Society for Developmental Biology (SDB) 72nd ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the SDB 2013 Annual Meeting. , ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3Climate change may have little impact on tropical lizards 2
... 2012 Researchers from Seattle Biomedical Research Institute (Seattle BioMed), ... uncovered new knowledge related to host-parasite interaction in severe malaria, ... in the brain and cause cerebral malaria the most ... published in the May 21 online edition of PNAS ( ...
... Darwin, assembling an evolutionary tree that shows the relationships between ... grandest and most daunting challenges facing biologists. Despite 150 ... no single diagram that displays the links between all of ... and microorganisms. Now, with $5.76 million from the U.S. ...
... build a grand tree of life that brings together everything ... the tiniest bacteria to the tallest tree. Scientists ... ever since Charles Darwin drew the first sketches in his ... branches of the tree of life, today there is still ...
Cached Biology News:New discoveries about severe malaria 2U-M biologist plays key role in effort to create first comprehensive tree of life 2U-M biologist plays key role in effort to create first comprehensive tree of life 3Researchers aim to assemble the tree of life for all 2 million named species 2Researchers aim to assemble the tree of life for all 2 million named species 3
Chemically Defined Lipid Concentrate...
...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
Request Info...
Biology Products: